Deutsche Bank Releases Amylin Pharmaceuticals' Breaking News
In a research report published earlier today by Deutsche Bank, Amylin Pharmaceuticals' (NASDAQ: AMLN) Bydureon is growing, but tracking behind Victoza.
According to Deutsche Bank, “IMS just released TRx data for the week ending March 16. We note that it is still very early in Bydureon launch (only 6 weeks of TRx data). Bydureon TRx for fifth full week was 1,947 vs. fifth full week for Victoza: 2,703. Cumulative TRx from launch to sixth week: Bydureon = 5,953 vs. Victoza= 7,849. While both Victoza and Byetta were down w/w in week ending 3/16/2012, Bydureon scripts grew by 19% w/w.”
Deutsche Bank maintains its Hold rating and $14 PT on Amylin Pharmaceuticals, which closed Friday at $15.52.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.